Dr. Reddy`s Laboratories is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75% Sodium Chloride Injection, 1,000 mg/100 mL (10 mg/mL) single-dose infusion bags to the consumer level, in the United States. The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL. Powered by Capital Market - Live News

Dr Reddys Laboratories has allotted 11,250 equity shares under ESOS on 06 March 2025. Powered by Capital Market - Live News

Dr Reddys Laboratories has allotted 20,155 equity shares of Re.1/- each of the Company, fully paid up, on 14 February 2025, to eligible employees pursuant to exercise of their Stock Options under Dr. Reddy`s Employees Stock Options Scheme, 2002. Powered by Capital Market - Live News

Net profit of Dr Reddy`s Laboratories rose 2.38% to Rs 1413.70 crore in the quarter ended December 2024 as against Rs 1380.90 crore during the previous quarter ended December 2023. Sales rose 15.85% to Rs 8358.60 crore in the quarter ended December 2024 as against Rs 7214.80 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales8358.607214.80 16 OPM %27.1928.04 - PBDT2345.702202.60 6 PBT1874.301829.10 2 NP1413.701380.90 2 Powered by Capital Market - Live News

Dr Reddys Laboratories has received reaffirmation in credit rating for bank facilities aggregating Rs 2,000 crore at ICRA AA+; Stable. Powered by Capital Market - Live News